KURAHIGH SIGNALOPERATIONAL10-K

KURA transitioned from a clinical-stage company to commercial operations with FDA approval of KOMZIFTI, but faced significant cash burn and financial deterioration during the commercialization launch.

The language changes reflect a fundamental business model shift from development-stage risks to commercialization execution risks, indicating FDA approval was achieved but market success remains uncertain. The dramatic swing from positive to negative operating cash flow coupled with massive increases in liabilities and declining equity suggests the commercial launch is consuming substantial resources without yet generating offsetting revenue.

Comparing 2026-03-05 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

KURA's financials show the costly transition to commercialization, with operating cash flow plummeting from +$134M to -$64M while net losses deepened 60% to $279M. The company significantly increased spending across all areas—SG&A expenses rose 56% to $120M, capital expenditures surged 1,306% to $6.6M, and total liabilities jumped 63% to $564M, while stockholder equity collapsed 58% to $174M. Despite some accounts receivable growth suggesting early sales, the overall picture reveals intense cash consumption during the commercial launch phase with profitability still distant.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+1306.4%
$472K$6.6M

Capital expenditure jumped 1306.4% — major investment cycle underway; assess returns on deployment.

Interest Expense
P&L
+576.4%
$229K$1.5M

Interest expense surged 576.4% — significant debt increase or rising rates materially impacting earnings.

Accounts Receivable
Balance Sheet
+327.4%
$2.1M$8.8M

Receivables surged 327.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Operating Cash Flow
Cash Flow
-147.7%
$134.3M-$64.1M

Operating cash flow fell 147.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Total Liabilities
Balance Sheet
+62.8%
$346.5M$564.2M

Liabilities grew 62.8% — significant increase in debt or obligations, assess impact on financial flexibility.

Net Income
P&L
-60.2%
-$174.0M-$278.7M

Net income declined 60.2% — review whether driven by operations, interest costs, or non-recurring items.

Stockholders Equity
Balance Sheet
-57.9%
$413.6M$174.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Income
P&L
-57.2%
-$193.2M-$303.6M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

SG&A Expense
P&L
+55.6%
$77.1M$120.0M

SG&A up 55.6% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Current Liabilities
Balance Sheet
+48.6%
$78.7M$117.0M

Current liabilities surged 48.6% — significant near-term obligations; verify ability to meet short-term debt.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-02-28
ADDED
The number of outstanding shares of the registrant s common stock as of February 27, 2026 was 88,329,759 shares.
Our ability to generate revenue is highly dependent on the successful commercialization of KOMZIFTI in the United States and continued global development of ziftomenib.
If we are unable to successfully commercialize KOMZIFTI in the United States, or to expand ziftomenib s indications of use or market opportunity, our ability to generate meaningful revenue or achieve profitability will be materially and adversely affected.
KOMZIFTI may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
If the market opportunities for KOMZIFTI are smaller than we believe, our revenue may be adversely affected, and our business may suffer.
+7 more — sign up free →
REMOVED
The number of outstanding shares of the registrant s common stock as of February 20, 2025 was 80,754,961 shares.
We are highly dependent on the success of our lead product candidate, ziftomenib, which is still in clinical development, and we cannot give any assurance that ziftomenib or any of our other product candidates will receive regulatory approval, which is necessary before they can be commercialized.
Even if our product candidates receive regulatory approval and are commercialized, they may be less competitive and generate less revenue than we anticipate.
Our discovery, preclinical and clinical development activities are primarily focused on the development of targeted therapeutics for patients with genetically defined cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs may never lead to marketable products.
We expect to incur losses over the next several years and may never achieve or maintain profitability.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →